Effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function, and long-term prognosis in chronic heart failure patients with dyslipidemia

Circulation Journal

Volumn 76, Issue 9, 2012, Pages 2130-2138

  Nakagomi, Akihiro ^a   Seino, Yoshihiko ^b   Kohashi, Keiichi ^a   Kosugi, Munenori ^a   Endoh, Yasumi ^a   Kusama, Yoshiki ^a   Atarashi, Hirotsugu ^a   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Cytokine; Dyslipidemia; Heart failure; Statin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; SPIRONOLACTONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE;

AGED; CHRONIC DISEASE; DYSLIPIDEMIAS; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; PROGNOSIS; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865498060     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1123     Document Type: Article

References (20)

1. El-Menyar AA. Cytokines and myocardial dysfunction: State of the art. J Cardiac Fail 2008; 14: 61-74.
2. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ Rec 1997; 81: 627-635.
3. Miyauchi K, Daida H. Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease. LDL-cholesterol: The lower, the better; Is it true for Asians? (Pro) Circ J 2010; 74: 1718-1730.
4. Zhou Q, Lioa JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818-826.
5. GISSI-HF investigators. Effects of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239.
6. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al; for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
7. Nakagomi A, Freedman SB, Gezcy CL. Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101: 1785-1791.
8. Nakagomi A, Seino Y, Endoh Y, Kusama Y, Atarashi H, Mizuno K. Upregulation of monocyte pro-inflammatory production by C-reactive protein is significantly related to ongoing myocardial damage and future cardiac events in patients with chronic heart failure. J Cardiac Fail 2010; 16: 562-571.
9. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621-630.
10. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-368.
11. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51: 415-426.
12. Tang WHW, Francis GS. Statin treatment for patients with heart failure. Nat Rev Cardiol 2010; 7: 249-255.
13. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-843.
14. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-508.
15. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
16. Australia and New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997; 349: 375-380.
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
18. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
19. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
20. Horwick TB, Hamilton MA, Maclellan WR, Fonarrow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216-224.